Freenome is an early cancer detection company developing blood-based screening tests to detect cancer when it is most treatable. The company's Personalized Cancer Detection approach combines multiomics, artificial intelligence and machine learning to develop screening tests tailored to the biology of individual cancers and the needs of specific patient populations.
Freenome is headquartered at 3300 Marina Boulevard, Brisbane, CA 94005.
Freenome is listed on the Nasdaq stock exchange under the ticker symbol “FRNM”.
Freenome went public via a merger with Perceptive Capital Solutions Corp. (PCSC), a special purpose acquisition company (SPAC), on July 20, 2026.
Freenome’s fiscal year ends on December 31.
Freenome does not offer a direct stock purchase plan at this time.
Freenome does not pay a dividend.
Quarterly and annual reports, as well as other SEC filings, can be accessed here on our Investor Relations website or directly from the SEC at www.sec.gov.
Ernst & Young LLP
Our transfer agent is Continental Stock Transfer & Trust Company.
You can join our Investor Relations email list here.
For investor inquiries, please contact investor-relations@freenome.com. You may also submit questions via the “Contact Us” page here.